ImmuCell Corp. Insider Surge: Directors Exercise Zero‑Cost Options, Signaling Confidence as Shares Skyrocket 39% YTD
Insider option activity at ImmuCell shows confidence in its rising biotech focus—free‑cost exercises suggest insiders see undervalued upside, potentially boosting future share performance.
3 minutes to read